Company Overview and News

BioSpace Movers and Shakers for Oct. 15

7h biospace
Pfizer – As global pharma giant Pfizer prepares for Albert Bourla to take over the reins of Pfizer from Chief Executive Officer Ian Read, the company has provided information on its senior leadership team.

CLVS / Clovis Oncology, Inc. FORM 8-K (Current Report)

2018-10-12 - 8

Recent IPO Gritstone Oncology: Neoantigen Targeted Personalized T Cell Therapy In Cancers

2018-10-12 seekingalpha - 1
The company was founded in 2015 by Andrew Allen, who also founded Clovis Oncology and Drs. Tim Chan and Naiyer Rizvi, both from Memorial Sloan Kettering Cancer Center.

Gritstone Oncology IPO: Data To Be Released In 2019

2018-10-08 seekingalpha - 3
It is quite beneficial that the company was able to seduce a long list of institutional investors. It tells a lot about the company.

Clovis Oncology: Some Positives Emerge

2018-10-03 seekingalpha - 2
Today, we revisit Clovis Oncology whose stock has been cut in half so far here in 2018.

Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC

2018-10-03 zacks - 1
Clovis Oncology, Inc. (CLVS - Free Report) announced that the FDA has granted Breakthrough Therapy designation for its cancer drug, Rubraca (rucaparib). The designation was granted for treating BRCA1/2 mutated metastatic castration resistant prostate cancer (mCRPC), based on initial data from phase II TRITON2 study. Currently, the study is evaluating the drug in mCRPC patients with BRCA mutations and ATM mutations.

Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

2018-10-03 zacks
Investors in Clovis Oncology, Inc. (CLVS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $40.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

Clovis Wins Big With FDA Update

2018-10-02 247wallst
Clovis Oncology Inc. (NASDAQ: CLVS) shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.

Clovis Oncology stock rises 10% premarket after 'breakthrough' designation from FDA

2018-10-02 marketwatch
Clovis Oncology Inc. CLVS, -0.78% shares rose nearly 10% in Tuesday premarket trade after the company's cancer drug Rubraca got a "breakthrough therapy" designation from the Food and Drug Administration. The designation could expedite the development and review of Rubraca by the FDA for BRCA1/2-mutated metastatic castration-resistant prostate cancer. The company plans to present the phase 2 trial data that "served as the basis of our [breakthrough therapy designation] at the [European Society for Medical Oncology] conference later this month," Clovis Chief Executive Patrick Mahaffy said.

Women Health a Prime Concern Worldwide: 3 Stocks in Focus

2018-09-28 zacks
Over the last few years, the ongoing debate about the effect of women’s health improvements on economic development is finally being taken as a matter of utmost relevance. However, the gap between words and action is still obvious as apparent from women of emerging countries whose limited or almost no access to education and employment make them extremely susceptible to life-threatening ailments.

On the Heels of bluebird bio Collaboration, Gritstone Secures $100 Million in IPO

2018-09-28 biospace - 2
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

2018-09-19 247wallst
Clovis Oncology Inc. (NASDAQ: CLVS) shares might not be showing it now, but the company is facing some heat from the U.S. Securities and Exchange Commission (SEC). The company, its chief executive officer and its former chief financial officer have agreed to pay more than $20 million in penalties to settle charges of misleading investors about the company’s developmental lung cancer drug.

Clovis, CEO, Ex-CFO Agree to Pay $20M+ to Settle SEC Charges

2018-09-19 genengnews
Clovis Oncology, its CEO, and its former CFO have agreed to pay more than $20 million to settle federal charges that they misled investors about the efficacy of rociletinib, a lung cancer drug candidate whose clinical trials the company halted in 2016. [Source: © ungureanusergiu/Fotolia]

Clovis Oncology to Pay the SEC $20 Million for Misleading Investors

2018-09-19 biospace
Clovis Oncology will pay more than $20 million in penalties to settle charges that Chief Executive Officer Patrick Mahaffy and its former Chief Financial Officer Erle Mast misleading investors about the company’s lung cancer treatment leading up to a public offering of stock.

Clovis Oncology, execs to pay $20 million to settle SEC charges

2018-09-18 reuters
WASHINGTON (Reuters) - U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

CLVS: Clovis Oncology Analysis and Research Report

2018-08-13 - Asif

Overview Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The company target its development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. The company's marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the Food and Drug Administration (“FDA”) as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for th...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CLVS / Clovis Oncology, Inc. on message board site Silicon Investor.

Clovis Onconlogy - CLVS Clovis Onconlogy - CLVS Clovis Onconlogy - CLVS
CUSIP: 189464100